An Investigator-sponsored Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous Non-small Cell Lung Cancer
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Afatinib (Primary) ; Prednisone
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Jul 2024 Planned End Date changed from 1 Sep 2025 to 1 Sep 2026.
- 09 Jul 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
- 17 Oct 2023 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.